{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T03:46:51Z","timestamp":1793245611245,"version":"4.5.0"},"reference-count":161,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1038\/s41584-025-01291-0","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T14:03:47Z","timestamp":1756735427000},"page":"657-670","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Immune-cell profiling to guide stratification and treatment of patients with rheumatic diseases"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9672-7746","authenticated-orcid":false,"given":"Deepak A.","family":"Rao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"key":"1291_CR1","first-page":"317","volume":"115","author":"C Bray","year":"2016","unstructured":"Bray, C. et al. Erythrocyte sedimentation rate and C-reactive protein measurements and their relevance in clinical medicine. WMJ 115, 317\u2013321 (2016).","journal-title":"WMJ"},{"key":"1291_CR2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11926-021-00984-1","volume":"23","author":"A Weinstein","year":"2021","unstructured":"Weinstein, A., Alexander, R. V. & Zack, D. J. A review of complement activation in SLE. Curr. Rheumatol. Rep. 23, 16 (2021).","journal-title":"Curr. Rheumatol. Rep."},{"key":"1291_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/cyto.b.21984","volume":"100","author":"S Sanjabi","year":"2021","unstructured":"Sanjabi, S. & Lear, S. New cytometry tools for immune monitoring during cancer immunotherapy. Cytom. B Clin. Cytom. 100, 10\u201318 (2021).","journal-title":"Cytom. B Clin. Cytom."},{"key":"1291_CR4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41584-019-0338-z","volume":"16","author":"FJ Hartmann","year":"2020","unstructured":"Hartmann, F. J. & Bendall, S. C. Immune monitoring using mass cytometry and related high-dimensional imaging approaches. Nat. Rev. Rheumatol. 16, 87\u201399 (2020).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1291_CR5","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.aan6828","volume":"358","author":"MJT Stubbington","year":"2017","unstructured":"Stubbington, M. J. T., Rozenblatt-Rosen, O., Regev, A. & Teichmann, S. A. Single-cell transcriptomics to explore the immune system in health and disease. Science 358, 58\u201363 (2017).","journal-title":"Science"},{"key":"1291_CR6","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/nmeth.4380","volume":"14","author":"M Stoeckius","year":"2017","unstructured":"Stoeckius, M. et al. Simultaneous epitope and transcriptome measurement in single cells. Nat. Methods 14, 865\u2013868 (2017).","journal-title":"Nat. Methods"},{"key":"1291_CR7","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1038\/nbt.3973","volume":"35","author":"VM Peterson","year":"2017","unstructured":"Peterson, V. M. et al. Multiplexed quantification of proteins and transcripts in single cells. Nat. Biotechnol. 35, 936\u2013939 (2017).","journal-title":"Nat. Biotechnol."},{"key":"1291_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4314","author":"E Becht","year":"2018","unstructured":"Becht, E. et al. Dimensionality reduction for visualizing single-cell data using UMAP. Nat. Biotechnol. https:\/\/doi.org\/10.1038\/nbt.4314 (2018).","journal-title":"Nat. Biotechnol."},{"key":"1291_CR9","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1261\/rna.078965.121","volume":"29","author":"S Zhang","year":"2023","unstructured":"Zhang, S., Li, X., Lin, J., Lin, Q. & Wong, K. C. Review of single-cell RNA-seq data clustering for cell-type identification and characterization. RNA 29, 517\u2013530 (2023).","journal-title":"RNA"},{"key":"1291_CR10","doi-asserted-by":"publisher","first-page":"eaaq0305","DOI":"10.1126\/scitranslmed.aaq0305","volume":"10","author":"CY Fonseka","year":"2018","unstructured":"Fonseka, C. Y. et al. Mixed-effects association of single cells identifies an expanded effector CD4+ T cell subset in rheumatoid arthritis. Sci. Transl. Med. 10, eaaq0305 (2018).","journal-title":"Sci. Transl. Med."},{"key":"1291_CR11","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41587-021-01066-4","volume":"40","author":"YA Reshef","year":"2022","unstructured":"Reshef, Y. A. et al. Co-varying neighborhood analysis identifies cell populations associated with phenotypes of interest from single-cell transcriptomics. Nat. Biotechnol. 40, 355\u2013363 (2022).","journal-title":"Nat. Biotechnol."},{"key":"1291_CR12","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41587-021-01033-z","volume":"40","author":"E Dann","year":"2022","unstructured":"Dann, E., Henderson, N. C., Teichmann, S. A., Morgan, M. D. & Marioni, J. C. Differential abundance testing on single-cell data using k-nearest neighbor graphs. Nat. Biotechnol. 40, 245\u2013253 (2022).","journal-title":"Nat. Biotechnol."},{"key":"1291_CR13","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1613849","volume":"377","author":"JH Stone","year":"2017","unstructured":"Stone, J. H. et al. Trial of tocilizumab in giant-cell arteritis. N. Engl. J. Med. 377, 317\u2013328 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1291_CR14","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1001\/jama.2022.15459","volume":"328","author":"V Devauchelle-Pensec","year":"2022","unstructured":"Devauchelle-Pensec, V. et al. Effect of tocilizumab on disease activity in patients with active polymyalgia rheumatica receiving glucocorticoid therapy: a randomized clinical trial. JAMA 328, 1053\u20131062 (2022).","journal-title":"JAMA"},{"key":"1291_CR15","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1177\/0961203316651742","volume":"25","author":"A Dima","year":"2016","unstructured":"Dima, A., Opris, D., Jurcut, C. & Baicus, C. Is there still a place for erythrocyte sedimentation rate and C-reactive protein in systemic lupus erythematosus? Lupus 25, 1173\u20131179 (2016).","journal-title":"Lupus"},{"key":"1291_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.102374","volume":"110","author":"M Aringer","year":"2020","unstructured":"Aringer, M. Inflammatory markers in systemic lupus erythematosus. J. Autoimmun. 110, 102374 (2020).","journal-title":"J. Autoimmun."},{"key":"1291_CR17","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1084\/jem.20021553","volume":"197","author":"L Bennett","year":"2003","unstructured":"Bennett, L. et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 197, 711\u2013723 (2003).","journal-title":"J. Exp. Med."},{"key":"1291_CR18","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1912196","volume":"382","author":"EF Morand","year":"2020","unstructured":"Morand, E. F. et al. Trial of anifrolumab in active systemic lupus erythematosus. N. Engl. J. Med. 382, 211\u2013221 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1291_CR19","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1016\/S2665-9913(21)00254-X","volume":"4","author":"FAH Cooles","year":"2022","unstructured":"Cooles, F. A. H. & Isaacs, J. D. The interferon gene signature as a clinically relevant biomarker in autoimmune rheumatic disease. Lancet Rheumatol. 4, e61\u2013e72 (2022).","journal-title":"Lancet Rheumatol."},{"key":"1291_CR20","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1136\/annrheumdis-2022-222212","volume":"81","author":"PE Lipsky","year":"2022","unstructured":"Lipsky, P. E. et al. Biological impact of iberdomide in patients with active systemic lupus erythematosus. Ann. Rheum. Dis. 81, 1136\u20131142 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"1291_CR21","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1136\/ard-2023-224537","volume":"83","author":"H Tanaka","year":"2024","unstructured":"Tanaka, H. et al. Extracting immunological and clinical heterogeneity across autoimmune rheumatic diseases by cohort-wide immunophenotyping. Ann. Rheum. Dis. 83, 242\u2013252 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"1291_CR22","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.3390\/ijms22052424","volume":"22","author":"M Burns","year":"2021","unstructured":"Burns, M. et al. Dysregulated CD38 expression on peripheral blood immune cell subsets in SLE. Int. J. Mol. Sci. 22, 2424 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1291_CR23","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.celrep.2019.12.014","volume":"30","author":"E Katsuyama","year":"2020","unstructured":"Katsuyama, E. et al. The CD38\/NAD\/SIRTUIN1\/EZH2 axis mitigates cytotoxic CD8 T cell function and identifies patients with SLE prone to infections. Cell Rep. 30, 112\u2013123.e4 (2020).","journal-title":"Cell Rep."},{"key":"1291_CR24","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.add1591","volume":"8","author":"R Wang","year":"2023","unstructured":"Wang, R. et al. Clonally expanded CD38hi cytotoxic CD8 T cells define the T cell infiltrate in checkpoint inhibitor-associated arthritis. Sci. Immunol. 8, eadd1591 (2023).","journal-title":"Sci. Immunol."},{"key":"1291_CR25","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.130062","volume":"4","author":"AV Bocharnikov","year":"2019","unstructured":"Bocharnikov, A. V. et al. PD-1hi CXCR5\u2212 T peripheral helper cells promote B cells responses in lupus via MAF and IL-21. JCI Insight 4, e130062 (2019).","journal-title":"JCI Insight"},{"key":"1291_CR26","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.immuni.2013.09.007","volume":"39","author":"J He","year":"2013","unstructured":"He, J. et al. Circulating precursor CCR7loPD-1hi CXCR5+ CD4+ T cells indicate Tfh cell activity and promote antibody responses upon antigen reexposure. Immunity 39, 770\u2013781 (2013).","journal-title":"Immunity"},{"key":"1291_CR27","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1093\/rheumatology\/kez228","volume":"58","author":"J Lin","year":"2019","unstructured":"Lin, J., Yu, Y., Ma, J., Ren, C. & Chen, W. PD-1+CXCR5\u2212CD4+T cells are correlated with the severity of systemic lupus erythematosus. Rheumatology 58, 2188\u20132192 (2019).","journal-title":"Rheumatology"},{"key":"1291_CR28","first-page":"1861","volume":"58","author":"A Makiyama","year":"2019","unstructured":"Makiyama, A. et al. Expanded circulating peripheral helper T cells in systemic lupus erythematosus: association with disease activity and B cell differentiation. Rheumatology 58, 1861\u20131869 (2019).","journal-title":"Rheumatology"},{"key":"1291_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03750-7","volume":"9","author":"S Wang","year":"2018","unstructured":"Wang, S. et al. IL-21 drives expansion and plasma cell differentiation of autoreactive CD11chiT-bet+ B cells in SLE. Nat. Commun. 9, 1758 (2018).","journal-title":"Nat. Commun."},{"key":"1291_CR30","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.immuni.2018.08.015","volume":"49","author":"SA Jenks","year":"2018","unstructured":"Jenks, S. A. et al. Distinct effector B cells induced by unregulated toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus. Immunity 49, 725\u2013739.e6 (2018).","journal-title":"Immunity"},{"key":"1291_CR31","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/ni.3175","volume":"16","author":"CM Tipton","year":"2015","unstructured":"Tipton, C. M. et al. Diversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus. Nat. Immunol. 16, 755\u2013765 (2015).","journal-title":"Nat. Immunol."},{"key":"1291_CR32","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/imr.13069","volume":"307","author":"KE Marks","year":"2022","unstructured":"Marks, K. E. & Rao, D. A. T peripheral helper cells in autoimmune diseases. Immunol. Rev. 307, 191\u2013202 (2022).","journal-title":"Immunol. Rev."},{"key":"1291_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1376933","volume":"15","author":"J Balog","year":"2024","unstructured":"Balog, J. et al. Comparative single-cell multiplex immunophenotyping of therapy-naive patients with rheumatoid arthritis, systemic sclerosis, and systemic lupus erythematosus shed light on disease-specific composition of the peripheral immune system. Front. Immunol. 15, 1376933 (2024).","journal-title":"Front. Immunol."},{"key":"1291_CR34","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1016\/j.cell.2021.03.056","volume":"184","author":"M Ota","year":"2021","unstructured":"Ota, M. et al. Dynamic landscape of immune cell-specific gene regulation in immune-mediated diseases. Cell 184, 3006\u20133021.e17 (2021).","journal-title":"Cell"},{"key":"1291_CR35","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.3899\/jrheum.190571","volume":"47","author":"S Chen","year":"2020","unstructured":"Chen, S. et al. Interleukin 17A and IL-17F expression and functional responses in rheumatoid arthritis and peripheral spondyloarthritis. J. Rheumatol. 47, 1606\u20131613 (2020).","journal-title":"J. Rheumatol."},{"key":"1291_CR36","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1056\/NEJMoa032534","volume":"350","author":"JC Edwards","year":"2004","unstructured":"Edwards, J. C. et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350, 2572\u20132581 (2004).","journal-title":"N. Engl. J. Med."},{"key":"1291_CR37","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.3899\/jrheum.121149","volume":"39","author":"PJ Mease","year":"2012","unstructured":"Mease, P. J. Is there a role for rituximab in the treatment of spondyloarthritis and psoriatic arthritis? J. Rheumatol. 39, 2235\u20132237 (2012).","journal-title":"J. Rheumatol."},{"key":"1291_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18513-6","volume":"11","author":"F Penkava","year":"2020","unstructured":"Penkava, F. et al. Single-cell sequencing reveals clonal expansions of pro-inflammatory synovial CD8 T cells expressing tissue-homing receptors in psoriatic arthritis. Nat. Commun. 11, 4767 (2020).","journal-title":"Nat. Commun."},{"key":"1291_CR39","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41586-023-06708-y","volume":"623","author":"F Zhang","year":"2023","unstructured":"Zhang, F. et al. Deconstruction of rheumatoid arthritis synovium defines inflammatory subtypes. Nature 623, 616\u2013624 (2023).","journal-title":"Nature"},{"key":"1291_CR40","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/s41590-019-0378-1","volume":"20","author":"F Zhang","year":"2019","unstructured":"Zhang, F. et al. Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry. Nat. Immunol. 20, 928\u2013942 (2019).","journal-title":"Nat. Immunol."},{"key":"1291_CR41","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1136\/annrheumdis-2021-220280","volume":"80","author":"N Yager","year":"2021","unstructured":"Yager, N. et al. Ex vivo mass cytometry analysis reveals a profound myeloid proinflammatory signature in psoriatic arthritis synovial fluid. Ann. Rheum. Dis. 80, 1559\u20131567 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"1291_CR42","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nature20810","volume":"542","author":"DA Rao","year":"2017","unstructured":"Rao, D. A. et al. Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis. Nature 542, 110\u2013114 (2017).","journal-title":"Nature"},{"key":"1291_CR43","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1093\/rheumatology\/kez169","volume":"58","author":"P Fortea-Gordo","year":"2019","unstructured":"Fortea-Gordo, P. et al. Two populations of circulating PD-1hiCD4 T cells with distinct B cell helping capacity are elevated in early rheumatoid arthritis. Rheumatology 58, 1662\u20131673 (2019).","journal-title":"Rheumatology"},{"key":"1291_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2025.102539","volume":"93","author":"JM Sowerby","year":"2025","unstructured":"Sowerby, J. M. & Rao, D. A. T cell-B cell interactions in human autoimmune diseases. Curr. Opin. Immunol. 93, 102539 (2025).","journal-title":"Curr. Opin. Immunol."},{"key":"1291_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112514","volume":"42","author":"GAM Povoleri","year":"2023","unstructured":"Povoleri, G. A. M. et al. Psoriatic and rheumatoid arthritis joints differ in the composition of CD8+ tissue-resident memory T cell subsets. Cell Rep. 42, 112514 (2023).","journal-title":"Cell Rep."},{"key":"1291_CR46","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/art.41156","volume":"72","author":"KJA Steel","year":"2020","unstructured":"Steel, K. J. A. et al. Polyfunctional, proinflammatory, tissue-resident memory phenotype and function of synovial interleukin-17A+CD8+ T cells in psoriatic arthritis. Arthritis Rheumatol. 72, 435\u2013447 (2020).","journal-title":"Arthritis Rheumatol."},{"key":"1291_CR47","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","volume":"373","author":"PJ Mease","year":"2015","unstructured":"Mease, P. J. et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N. Engl. J. Med. 373, 1329\u20131339 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1291_CR48","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","volume":"386","author":"IB McInnes","year":"2015","unstructured":"McInnes, I. B. et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 386, 1137\u20131146 (2015).","journal-title":"Lancet"},{"key":"1291_CR49","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1136\/annrheumdis-2019-215349","volume":"78","author":"Z Qaiyum","year":"2019","unstructured":"Qaiyum, Z., Gracey, E., Yao, Y. & Inman, R. D. Integrin and transcriptomic profiles identify a distinctive synovial CD8+ T cell subpopulation in spondyloarthritis. Ann. Rheum. Dis. 78, 1566\u20131575 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"1291_CR50","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abo0686","volume":"14","author":"AH Jonsson","year":"2022","unstructured":"Jonsson, A. H. et al. Granzyme K+ CD8 T cells form a core population in inflamed human tissue. Sci. Transl. Med. 14, eabo0686 (2022).","journal-title":"Sci. Transl. Med."},{"key":"1291_CR51","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1002\/1529-0131(199907)42:7<1481::AID-ANR23>3.0.CO;2-E","volume":"42","author":"RJ Reece","year":"1999","unstructured":"Reece, R. J., Canete, J. D., Parsons, W. J., Emery, P. & Veale, D. J. Distinct vascular patterns of early synovitis in psoriatic, reactive, and rheumatoid arthritis. Arthritis Rheum. 42, 1481\u20131484 (1999).","journal-title":"Arthritis Rheum."},{"key":"1291_CR52","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1136\/annrheumdis-2021-221761","volume":"81","author":"A Floudas","year":"2022","unstructured":"Floudas, A. et al. Distinct stromal and immune cell interactions shape the pathogenesis of rheumatoid and psoriatic arthritis. Ann. Rheum. Dis. 81, 1224\u20131242 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"1291_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.629726","volume":"11","author":"F Abji","year":"2020","unstructured":"Abji, F. et al. Proteinase-mediated macrophage signaling in psoriatic arthritis. Front. Immunol. 11, 629726 (2020).","journal-title":"Front. Immunol."},{"key":"1291_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2023.109679","volume":"253","author":"GE Fragoulis","year":"2023","unstructured":"Fragoulis, G. E. et al. Distinct innate and adaptive immunity phenotypic profile at the circulating single-cell level in psoriatic arthritis. Clin. Immunol. 253, 109679 (2023).","journal-title":"Clin. Immunol."},{"key":"1291_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1447213","volume":"15","author":"B Li","year":"2024","unstructured":"Li, B. et al. Differential immunological profiles in seronegative versus seropositive rheumatoid arthritis: Th17\/Treg dysregulation and IL-4. Front. Immunol. 15, 1447213 (2024).","journal-title":"Front. Immunol."},{"key":"1291_CR56","doi-asserted-by":"publisher","unstructured":"Bhamidipati, K. et al. Spatial patterning of fibroblast TGF\u03b2 signaling underlies treatment resistance in rheumatoid arthritis. Preprint at bioRxiv, https:\/\/doi.org\/10.1101\/2025.03.14.642821 (2025).","DOI":"10.1101\/2025.03.14.642821"},{"key":"1291_CR57","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","volume":"26","author":"J Naidoo","year":"2015","unstructured":"Naidoo, J. et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann. Oncol. 26, 2375\u20132391 (2015).","journal-title":"Ann. Oncol."},{"key":"1291_CR58","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.rdc.2022.02.002","volume":"48","author":"N Ghosh","year":"2022","unstructured":"Ghosh, N. & Bass, A. R. Rheumatic complications of immune checkpoint inhibitors. Rheum. Dis. Clin. North. Am. 48, 411\u2013428 (2022).","journal-title":"Rheum. Dis. Clin. North. Am."},{"key":"1291_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152110","volume":"58","author":"N Ghosh","year":"2023","unstructured":"Ghosh, N. et al. Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica: a scoping review by the OMERACT irAE working group. Semin. Arthritis Rheum. 58, 152110 (2023).","journal-title":"Semin. Arthritis Rheum."},{"key":"1291_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29539-3","volume":"13","author":"ST Kim","year":"2022","unstructured":"Kim, S. T. et al. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat. Commun. 13, 1970 (2022).","journal-title":"Nat. Commun."},{"key":"1291_CR61","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1002\/eji.202048797","volume":"51","author":"P Maschmeyer","year":"2021","unstructured":"Maschmeyer, P. et al. Antigen-driven PD-1+ TOX+ BHLHE40+ and PD-1+ TOX+ EOMES+ T lymphocytes regulate juvenile idiopathic arthritis in situ. Eur. J. Immunol. 51, 915\u2013929 (2021).","journal-title":"Eur. J. Immunol."},{"key":"1291_CR62","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/nrrheum.2017.220","volume":"14","author":"G Barturen","year":"2018","unstructured":"Barturen, G., Beretta, L., Cervera, R., Van Vollenhoven, R. & Alarc\u00f3n-Riquelme, M. E. Moving towards a molecular taxonomy of autoimmune rheumatic diseases. Nat. Rev. Rheumatol. 14, 75\u201393 (2018).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1291_CR63","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1097\/BOR.0b013e32835fd8eb","volume":"25","author":"C Pitzalis","year":"2013","unstructured":"Pitzalis, C., Kelly, S. & Humby, F. New learnings on the pathophysiology of RA from synovial biopsies. Curr. Opin. Rheumatol. 25, 334\u2013344 (2013).","journal-title":"Curr. Opin. Rheumatol."},{"key":"1291_CR64","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1016\/j.celrep.2019.07.091","volume":"28","author":"MJ Lewis","year":"2019","unstructured":"Lewis, M. J. et al. Molecular portraits of early rheumatoid arthritis identify clinical and treatment response phenotypes. Cell Rep. 28, 2455\u20132470.e5 (2019).","journal-title":"Cell Rep."},{"key":"1291_CR65","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nri3700","volume":"14","author":"C Pitzalis","year":"2014","unstructured":"Pitzalis, C., Jones, G. W., Bombardieri, M. & Jones, S. A. Ectopic lymphoid-like structures in infection, cancer and autoimmunity. Nat. Rev. Immunol. 14, 447\u2013462 (2014).","journal-title":"Nat. Rev. Immunol."},{"key":"1291_CR66","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1136\/annrheumdis-2018-214539","volume":"78","author":"F Humby","year":"2019","unstructured":"Humby, F. et al. Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients. Ann. Rheum. Dis. 78, 761\u2013772 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"1291_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49186-0","volume":"15","author":"G Dunlap","year":"2024","unstructured":"Dunlap, G. et al. Clonal associations between lymphocyte subsets and functional states in rheumatoid arthritis synovium. Nat. Commun. 15, 4991 (2024).","journal-title":"Nat. Commun."},{"key":"1291_CR68","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1002\/art.42949","volume":"76","author":"LE Durham","year":"2024","unstructured":"Durham, L. E. et al. Substantive similarities between synovial fluid and synovial tissue t cells in inflammatory arthritis via single-cell RNA and T cell receptor sequencing. Arthritis Rheumatol. 76, 1594\u20131601 (2024).","journal-title":"Arthritis Rheumatol."},{"key":"1291_CR69","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1136\/ard-2024-226228","volume":"84","author":"S Kubo","year":"2025","unstructured":"Kubo, S. et al. Peripheral blood immunophenotypic diversity in patients with rheumatoid arthritis and its impact on therapeutic responsiveness. Ann. Rheum. Dis. 84, 210\u2013220 (2025).","journal-title":"Ann. Rheum. Dis."},{"key":"1291_CR70","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adk1643","volume":"9","author":"M Goto","year":"2024","unstructured":"Goto, M. et al. Age-associated CD4+ T cells with B cell-promoting functions are regulated by ZEB2 in autoimmunity. Sci. Immunol. 9, eadk1643 (2024).","journal-title":"Sci. Immunol."},{"key":"1291_CR71","doi-asserted-by":"publisher","DOI":"10.1172\/jci181034","author":"A Horisberger","year":"2025","unstructured":"Horisberger, A. et al. Blood immunophenotyping identifies distinct kidney histopathology and outcomes in patients with lupus nephritis. J. Clin. Invest. https:\/\/doi.org\/10.1172\/jci181034 (2025).","journal-title":"J. Clin. Invest."},{"key":"1291_CR72","doi-asserted-by":"publisher","unstructured":"Sasaki, T. et al. Clonal relationships between Tph and Tfh cells in patients with SLE and in murine lupus. Preprint at bioRxiv, https:\/\/doi.org\/10.1101\/2025.01.27.635189 (2025).","DOI":"10.1101\/2025.01.27.635189"},{"key":"1291_CR73","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf1970","volume":"376","author":"RK Perez","year":"2022","unstructured":"Perez, R. K. et al. Single-cell RNA-seq reveals cell type-specific molecular and genetic associations to lupus. Science 376, eabf1970 (2022).","journal-title":"Science"},{"key":"1291_CR74","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1038\/s41590-020-0743-0","volume":"21","author":"D Nehar-Belaid","year":"2020","unstructured":"Nehar-Belaid, D. et al. Mapping systemic lupus erythematosus heterogeneity at the single-cell level. Nat. Immunol. 21, 1094\u20131106 (2020).","journal-title":"Nat. Immunol."},{"key":"1291_CR75","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn2263","volume":"14","author":"AC Billi","year":"2022","unstructured":"Billi, A. C. et al. Nonlesional lupus skin contributes to inflammatory education of myeloid cells and primes for cutaneous inflammation. Sci. Transl. Med. 14, eabn2263 (2022).","journal-title":"Sci. Transl. Med."},{"key":"1291_CR76","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.156341","volume":"7","author":"GS Dunlap","year":"2022","unstructured":"Dunlap, G. S. et al. Single-cell transcriptomics reveals distinct effector profiles of infiltrating T cells in lupus skin and kidney. JCI Insight 7, e156341 (2022).","journal-title":"JCI Insight"},{"key":"1291_CR77","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/s41590-019-0398-x","volume":"20","author":"A Arazi","year":"2019","unstructured":"Arazi, A. et al. The immune cell landscape in kidneys of patients with lupus nephritis. Nat. Immunol. 20, 902\u2013914 (2019).","journal-title":"Nat. Immunol."},{"key":"1291_CR78","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/s41590-019-0386-1","volume":"20","author":"E Der","year":"2019","unstructured":"Der, E. et al. Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways. Nat. Immunol. 20, 915\u2013927 (2019).","journal-title":"Nat. Immunol."},{"key":"1291_CR79","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adl1666","volume":"16","author":"P Danaher","year":"2024","unstructured":"Danaher, P. et al. Childhood-onset lupus nephritis is characterized by complex interactions between kidney stroma and infiltrating immune cells. Sci. Transl. Med. 16, eadl1666 (2024).","journal-title":"Sci. Transl. Med."},{"key":"1291_CR80","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.cell.2016.03.008","volume":"165","author":"R Banchereau","year":"2016","unstructured":"Banchereau, R. et al. Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell 165, 551\u2013565 (2016).","journal-title":"Cell"},{"key":"1291_CR81","doi-asserted-by":"publisher","first-page":"100291","DOI":"10.1016\/j.eclinm.2020.100291","volume":"20","author":"JM Guthridge","year":"2020","unstructured":"Guthridge, J. M. et al. Adults with systemic lupus exhibit distinct molecular phenotypes in a cross-sectional study. eClinicalMedicine 20, 100291 (2020).","journal-title":"eClinicalMedicine"},{"key":"1291_CR82","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-023-01237-9","volume":"15","author":"EL Hubbard","year":"2023","unstructured":"Hubbard, E. L. et al. Analysis of transcriptomic features reveals molecular endotypes of SLE with clinical implications. Genome Med. 15, 84 (2023).","journal-title":"Genome Med."},{"key":"1291_CR83","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.860726","volume":"13","author":"P Garantziotis","year":"2022","unstructured":"Garantziotis, P. et al. Molecular taxonomy of systemic lupus erythematosus through data-driven patient stratification: molecular endotypes and cluster-tailored drugs. Front. Immunol. 13, 860726 (2022).","journal-title":"Front. Immunol."},{"key":"1291_CR84","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.635615","volume":"12","author":"H Rincon-Arevalo","year":"2021","unstructured":"Rincon-Arevalo, H. et al. Deep phenotyping of CD11c+ B cells in systemic autoimmunity and controls. Front. Immunol. 12, 635615 (2021).","journal-title":"Front. Immunol."},{"key":"1291_CR85","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.clim.2004.05.010","volume":"113","author":"C Wehr","year":"2004","unstructured":"Wehr, C. et al. A new CD21low B cell population in the peripheral blood of patients with SLE. Clin. Immunol. 113, 161\u2013171 (2004).","journal-title":"Clin. Immunol."},{"key":"1291_CR86","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1002\/art.40180","volume":"69","author":"S Kubo","year":"2017","unstructured":"Kubo, S. et al. Peripheral immunophenotyping identifies three subgroups based on T cell heterogeneity in lupus patients. Arthritis Rheumatol. 69, 2029\u20132037 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"1291_CR87","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1002\/art.42248","volume":"74","author":"T Sasaki","year":"2022","unstructured":"Sasaki, T. et al. Longitudinal immune cell profiling in early systemic lupus erythematosus. Arthritis Rheumatol. 74, 1808\u20131821 (2022).","journal-title":"Arthritis Rheumatol."},{"key":"1291_CR88","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1002\/art.39020","volume":"67","author":"JY Choi","year":"2015","unstructured":"Choi, J. Y. et al. Circulating follicular helper-like T cells in systemic lupus erythematosus: association with disease activity. Arthritis Rheumatol. 67, 988\u2013999 (2015).","journal-title":"Arthritis Rheumatol."},{"key":"1291_CR89","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/imr.12741","volume":"288","author":"SA Jenks","year":"2019","unstructured":"Jenks, S. A., Cashman, K. S., Woodruff, M. C., Lee, F. E. & Sanz, I. Extrafollicular responses in humans and SLE. Immunol. Rev. 288, 136\u2013148 (2019).","journal-title":"Immunol. Rev."},{"key":"1291_CR90","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.3389\/fimmu.2018.01924","volume":"9","author":"DA Rao","year":"2018","unstructured":"Rao, D. A. T cells that help B cells in chronically inflamed tissues. Front. Immunol. 9, 1924 (2018).","journal-title":"Front. Immunol."},{"key":"1291_CR91","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s13075-022-02956-x","volume":"24","author":"M Skougaard","year":"2022","unstructured":"Skougaard, M. et al. Four emerging immune cellular blood phenotypes associated with disease duration and activity established in psoriatic arthritis. Arthritis Res. Ther. 24, 262 (2022).","journal-title":"Arthritis Res. Ther."},{"key":"1291_CR92","doi-asserted-by":"publisher","unstructured":"Urbanski, G. et al. Single-cell RNA sequencing of peripheral blood defines two immunological subtypes of Sj\u00f6gren\u2019s disease. Preprint at bioRxiv, 2025.2002.2027.640483, https:\/\/doi.org\/10.1101\/2025.02.27.640483 (2025).","DOI":"10.1101\/2025.02.27.640483"},{"key":"1291_CR93","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","volume":"320","author":"D Aletaha","year":"2018","unstructured":"Aletaha, D. & Smolen, J. S. Diagnosis and management of rheumatoid arthritis: a review. JAMA 320, 1360\u20131372 (2018).","journal-title":"JAMA"},{"key":"1291_CR94","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","volume":"377","author":"SV Navarra","year":"2011","unstructured":"Navarra, S. V. et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377, 721\u2013731 (2011).","journal-title":"Lancet"},{"key":"1291_CR95","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","volume":"397","author":"BH Rovin","year":"2021","unstructured":"Rovin, B. H. et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 397, 2070\u20132080 (2021).","journal-title":"Lancet"},{"key":"1291_CR96","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3390\/jpm9040046","volume":"9","author":"B Mulhearn","year":"2019","unstructured":"Mulhearn, B., Barton, A. & Viatte, S. Using the immunophenotype to predict response to biologic drugs in rheumatoid arthritis. J. Pers. Med. 9, 46 (2019).","journal-title":"J. Pers. Med."},{"key":"1291_CR97","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002570","volume":"8","author":"MHM Wientjes","year":"2022","unstructured":"Wientjes, M. H. M., den Broeder, A. A., Welsing, P. M. J., Verhoef, L. M. & van den Bemt, B. J. F. Prediction of response to anti-TNF treatment using laboratory biomarkers in patients with rheumatoid arthritis: a systematic review. RMD Open. 8, e002570 (2022).","journal-title":"RMD Open."},{"key":"1291_CR98","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s40744-021-00330-y","volume":"8","author":"S Cohen","year":"2021","unstructured":"Cohen, S. et al. A molecular signature response classifier to predict inadequate response to tumor necrosis factor-\u03b1 inhibitors: the NETWORK-004 prospective observational study. Rheumatol. Ther. 8, 1159\u20131176 (2021).","journal-title":"Rheumatol. Ther."},{"key":"1291_CR99","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s40744-020-00226-3","volume":"7","author":"MJ Bergman","year":"2020","unstructured":"Bergman, M. J. et al. Clinical utility and cost savings in predicting inadequate response to anti-TNF therapies in rheumatoid arthritis. Rheumatol. Ther. 7, 775\u2013792 (2020).","journal-title":"Rheumatol. Ther."},{"key":"1291_CR100","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1093\/rheumatology\/keab454","volume":"61","author":"J Aldridge","year":"2022","unstructured":"Aldridge, J. et al. Blood PD-1+TFh and CTLA-4+CD4+ T cells predict remission after CTLA-4Ig treatment in early rheumatoid arthritis. Rheumatology 61, 1233\u20131242 (2022).","journal-title":"Rheumatology"},{"key":"1291_CR101","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1093\/rheumatology\/keae090","volume":"64","author":"I Monjo-Henry","year":"2025","unstructured":"Monjo-Henry, I. et al. Circulating Tfh cells are differentially modified by abatacept or TNF blockers and predict treatment response in rheumatoid arthritis. Rheumatology 64, 517\u2013525 (2025).","journal-title":"Rheumatology"},{"key":"1291_CR102","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1038\/s41590-020-0744-z","volume":"21","author":"NM Edner","year":"2020","unstructured":"Edner, N. M. et al. Follicular helper T cell profiles predict response to costimulation blockade in type 1 diabetes. Nat. Immunol. 21, 1244\u20131255 (2020).","journal-title":"Nat. Immunol."},{"key":"1291_CR103","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.1002\/art.30599","volume":"63","author":"J Sellam","year":"2011","unstructured":"Sellam, J. et al. Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 63, 3692\u20133701 (2011).","journal-title":"Arthritis Rheum."},{"key":"1291_CR104","doi-asserted-by":"publisher","DOI":"10.1186\/ar2686","volume":"11","author":"B M\u00f6ller","year":"2009","unstructured":"M\u00f6ller, B. et al. Class-switched B cells display response to therapeutic B-cell depletion in rheumatoid arthritis. Arthritis Res. Ther. 11, R62 (2009).","journal-title":"Arthritis Res. Ther."},{"key":"1291_CR105","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1002\/art.23473","volume":"58","author":"P Roll","year":"2008","unstructured":"Roll, P., D\u00f6rner, T. & Tony, H. P. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum. 58, 1566\u20131575 (2008).","journal-title":"Arthritis Rheum."},{"key":"1291_CR106","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1136\/annrheumdis-2013-204544","volume":"74","author":"EM Vital","year":"2015","unstructured":"Vital, E. M., Dass, S., Buch, M. H., Rawstron, A. C. & Emery, P. An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trial. Ann. Rheum. Dis. 74, 1195\u20131201 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"1291_CR107","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45213-2","volume":"15","author":"KF Baker","year":"2024","unstructured":"Baker, K. F. et al. Single-cell insights into immune dysregulation in rheumatoid arthritis flare versus drug-free remission. Nat. Commun. 15, 1063 (2024).","journal-title":"Nat. Commun."},{"key":"1291_CR108","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1056\/NEJMoa2004114","volume":"383","author":"DE Orange","year":"2020","unstructured":"Orange, D. E. et al. RNA identification of PRIME cells predicting rheumatoid arthritis flares. N. Engl. J. Med. 383, 218\u2013228 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1291_CR109","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/s41591-022-01789-0","volume":"28","author":"F Rivellese","year":"2022","unstructured":"Rivellese, F. et al. Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. Nat. Med. 28, 1256\u20131268 (2022).","journal-title":"Nat. Med."},{"key":"1291_CR110","doi-asserted-by":"publisher","first-page":"845","DOI":"10.3389\/fimmu.2020.00845","volume":"11","author":"A Nerviani","year":"2020","unstructured":"Nerviani, A. et al. A pauci-immune synovial pathotype predicts inadequate response to TNF\u03b1-blockade in rheumatoid arthritis patients. Front. Immunol. 11, 845 (2020).","journal-title":"Front. Immunol."},{"key":"1291_CR111","doi-asserted-by":"publisher","first-page":"e648","DOI":"10.1016\/S2665-9913(23)00241-2","volume":"5","author":"F Rivellese","year":"2023","unstructured":"Rivellese, F. et al. Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials. Lancet Rheumatol. 5, e648\u2013e659 (2023).","journal-title":"Lancet Rheumatol."},{"key":"1291_CR112","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S0140-6736(20)32341-2","volume":"397","author":"F Humby","year":"2021","unstructured":"Humby, F. et al. Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet 397, 305\u2013317 (2021).","journal-title":"Lancet"},{"key":"1291_CR113","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/s41591-020-0939-8","volume":"26","author":"S Alivernini","year":"2020","unstructured":"Alivernini, S. et al. Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis. Nat. Med. 26, 1295\u20131306 (2020).","journal-title":"Nat. Med."},{"key":"1291_CR114","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1016\/j.immuni.2024.11.004","volume":"57","author":"L MacDonald","year":"2024","unstructured":"MacDonald, L. et al. Synovial tissue myeloid dendritic cell subsets exhibit distinct tissue-niche localization and function in health and rheumatoid arthritis. Immunity 57, 2843\u20132862.e12 (2024).","journal-title":"Immunity"},{"key":"1291_CR115","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1038\/s41590-024-01994-8","volume":"25","author":"T Thomas","year":"2024","unstructured":"Thomas, T. et al. A longitudinal single-cell atlas of anti-tumour necrosis factor treatment in inflammatory bowel disease. Nat. Immunol. 25, 2152\u20132165 (2024).","journal-title":"Nat. Immunol."},{"key":"1291_CR116","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1093\/bjd\/ljad089","volume":"189","author":"LM Carter","year":"2023","unstructured":"Carter, L. M., Wigston, Z., Laws, P. & Vital, E. M. Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers. Br. J. Dermatol. 189, 210\u2013218 (2023).","journal-title":"Br. J. Dermatol."},{"key":"1291_CR117","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1136\/ard-2023-225445","volume":"83","author":"T Baker","year":"2024","unstructured":"Baker, T. et al. Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials. Ann. Rheum. Dis. 83, 1018\u20131027 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"1291_CR118","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2018-000286","volume":"5","author":"KA Casey","year":"2018","unstructured":"Casey, K. A. et al. Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE. Lupus Sci. Med. 5, e000286 (2018).","journal-title":"Lupus Sci. Med."},{"key":"1291_CR119","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/s41586-024-07627-2","volume":"631","author":"C Law","year":"2024","unstructured":"Law, C. et al. Interferon subverts an AHR-JUN axis to promote CXCL13+ T cells in lupus. Nature 631, 857\u2013866 (2024).","journal-title":"Nature"},{"key":"1291_CR120","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1136\/annrheumdis-2021-221425","volume":"81","author":"EM Vital","year":"2022","unstructured":"Vital, E. M. et al. Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. Ann. Rheum. Dis. 81, 951\u2013961 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"1291_CR121","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/ard-2024-226051","volume":"84","author":"GS Moysidou","year":"2025","unstructured":"Moysidou, G. S. et al. Molecular basis for the disease-modifying effects of belimumab in systemic lupus erythematosus and molecular predictors of early response: blood transcriptome analysis implicates the innate immunity and DNA damage response pathways. Ann. Rheum. Dis. 84, 262\u2013273 (2025).","journal-title":"Ann. Rheum. Dis."},{"key":"1291_CR122","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1002\/art.39950","volume":"69","author":"RW Hoffman","year":"2017","unstructured":"Hoffman, R. W. et al. Gene expression and pharmacodynamic changes in 1,760 systemic lupus erythematosus patients from two phase III trials of BAFF blockade with tabalumab. Arthritis Rheumatol. 69, 643\u2013654 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"1291_CR123","doi-asserted-by":"publisher","first-page":"3375","DOI":"10.1016\/j.cell.2022.07.021","volume":"185","author":"M Nakano","year":"2022","unstructured":"Nakano, M. et al. Distinct transcriptome architectures underlying lupus establishment and exacerbation. Cell 185, 3375\u20133389.e21 (2022).","journal-title":"Cell"},{"key":"1291_CR124","first-page":"1259","volume":"43","author":"W Sun","year":"2025","unstructured":"Sun, W. et al. Heterogeneity of peripheral immune cell landscape in systemic lupus erythematosus patients after belimumab treatment. Clin. Exp. Rheumatol. 43, 1259\u20131276 (2025).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1291_CR125","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2023-000976","volume":"10","author":"S Maeda","year":"2023","unstructured":"Maeda, S. et al. High-dimensional analysis of T-cell profiling variations following belimumab treatment in systemic lupus erythematosus. Lupus Sci. Med. 10, e000976 (2023).","journal-title":"Lupus Sci. Med."},{"key":"1291_CR126","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1177\/0961203318797425","volume":"27","author":"M Prete","year":"2018","unstructured":"Prete, M. et al. Belimumab restores Treg\/Th17 balance in patients with refractory systemic lupus erythematosus. Lupus 27, 1926\u20131935 (2018).","journal-title":"Lupus"},{"key":"1291_CR127","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1002\/art.42652","volume":"75","author":"JT Merrill","year":"2023","unstructured":"Merrill, J. T. et al. Obexelimab in systemic lupus erythematosus with exploration of response based on gene pathway co-expression patterns: a double-blind, randomized, placebo-controlled, phase 2 trial. Arthritis Rheumatol. 75, 2185\u20132194 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"1291_CR128","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1136\/annrheumdis-2017-212916","volume":"77","author":"PH Schafer","year":"2018","unstructured":"Schafer, P. H. et al. Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus. Ann. Rheum. Dis. 77, 1516\u20131523 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"1291_CR129","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller, F. et al. CD19 CAR T-cell therapy in autoimmune disease \u2014 a case series with follow-up. N. Engl. J. Med. 390, 687\u2013700 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1291_CR130","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1056\/NEJMc2408786","volume":"391","author":"M Hagen","year":"2024","unstructured":"Hagen, M. et al. BCMA-targeted T-cell-engager therapy for autoimmune disease. N. Engl. J. Med. 391, 867\u2013869 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1291_CR131","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1056\/NEJMc2407150","volume":"391","author":"T Alexander","year":"2024","unstructured":"Alexander, T., Kr\u00f6nke, J., Cheng, Q., Keller, U. & Kr\u00f6nke, G. Teclistamab-induced remission in refractory systemic lupus erythematosus. N. Engl. J. Med. 391, 864\u2013866 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1291_CR132","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.179433","volume":"9","author":"A Wilhelm","year":"2024","unstructured":"Wilhelm, A. et al. Selective CAR T cell-mediated B cell depletion suppresses IFN signature in SLE. JCI Insight 9, e179433 (2024).","journal-title":"JCI Insight"},{"key":"1291_CR133","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ajhg.2017.01.006","volume":"100","author":"RB Ramoni","year":"2017","unstructured":"Ramoni, R. B. et al. The Undiagnosed Diseases Network: accelerating discovery about health and disease. Am. J. Hum. Genet. 100, 185\u2013192 (2017).","journal-title":"Am. J. Hum. Genet."},{"key":"1291_CR134","doi-asserted-by":"publisher","DOI":"10.1172\/JCI169619","volume":"133","author":"AA Mueller","year":"2023","unstructured":"Mueller, A. A. et al. High-dimensional immunophenotyping reveals immune cell aberrations in patients with undiagnosed inflammatory and autoimmune diseases. J. Clin. Invest. 133, e169619 (2023).","journal-title":"J. Clin. Invest."},{"key":"1291_CR135","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.ajhg.2017.04.003","volume":"100","author":"KM Boycott","year":"2017","unstructured":"Boycott, K. M. et al. International cooperation to enable the diagnosis of all rare genetic diseases. Am. J. Hum. Genet. 100, 695\u2013705 (2017).","journal-title":"Am. J. Hum. Genet."},{"key":"1291_CR136","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/s41591-019-0457-8","volume":"25","author":"L Fr\u00e9sard","year":"2019","unstructured":"Fr\u00e9sard, L. et al. Identification of rare-disease genes using blood transcriptome sequencing and large control cohorts. Nat. Med. 25, 911\u2013919 (2019).","journal-title":"Nat. Med."},{"key":"1291_CR137","doi-asserted-by":"publisher","first-page":"a006198","DOI":"10.1101\/mcs.a006198","volume":"8","author":"SB Montgomery","year":"2022","unstructured":"Montgomery, S. B., Bernstein, J. A. & Wheeler, M. T. Toward transcriptomics as a primary tool for rare disease investigation. Cold Spring Harb. Mol. Case Stud. 8, a006198 (2022).","journal-title":"Cold Spring Harb. Mol. Case Stud."},{"key":"1291_CR138","doi-asserted-by":"publisher","unstructured":"Liu, C. et al. Multi-lineage transcriptional and cell communication signatures define pathways in individuals at-risk for developing rheumatoid arthritis that initiate and perpetuate disease. Preprint at bioRxiv, https:\/\/doi.org\/10.1101\/2025.02.08.619913 (2025).","DOI":"10.1101\/2025.02.08.619913"},{"key":"1291_CR139","doi-asserted-by":"publisher","DOI":"10.1172\/JCI185217","volume":"135","author":"J Inamo","year":"2025","unstructured":"Inamo, J. et al. Deep immunophenotyping reveals circulating activated lymphocytes in individuals at risk for rheumatoid arthritis. J. Clin. Investig. 135, e185217 (2025).","journal-title":"J. Clin. Investig."},{"key":"1291_CR140","doi-asserted-by":"publisher","unstructured":"Sasaki, T. et al. A CD57+ cytotoxic CD8 T cell subset associated with fibrotic lung disease in systemic sclerosis. Preprint at bioRxiv, 2025.2001.2027.635121, https:\/\/doi.org\/10.1101\/2025.01.27.635121 (2025).","DOI":"10.1101\/2025.01.27.635121"},{"key":"1291_CR141","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1002\/art.23404","volume":"58","author":"R Biesen","year":"2008","unstructured":"Biesen, R. et al. Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus. Arthritis Rheum. 58, 1136\u20131145 (2008).","journal-title":"Arthritis Rheum."},{"key":"1291_CR142","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1136\/annrheumdis-2012-201586","volume":"72","author":"T Rose","year":"2013","unstructured":"Rose, T. et al. IFN\u03b1 and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus. Ann. Rheum. Dis. 72, 1639\u20131645 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"1291_CR143","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2024.105711","volume":"156","author":"H Fang","year":"2025","unstructured":"Fang, H., Wang, S. A., Medeiros, L. J. & Wang, W. Application of flow cytometry immunophenotypic analysis for the diagnosis of mature B-cell lymphomas\/leukemias. Hum. Pathol. 156, 105711 (2025).","journal-title":"Hum. Pathol."},{"key":"1291_CR144","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.iac.2025.01.008","volume":"45","author":"AA Nguyen","year":"2025","unstructured":"Nguyen, A. A. & Platt, C. D. Flow cytometry-based immune phenotyping of T and B lymphocytes in the evaluation of immunodeficiency and immune dysregulation. Immunol. Allergy Clin. North. Am. 45, 189\u2013203 (2025).","journal-title":"Immunol. Allergy Clin. North. Am."},{"key":"1291_CR145","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2023.103088","volume":"140","author":"B LaBere","year":"2023","unstructured":"LaBere, B. et al. Clinical utility of measuring CD4+ T follicular cells in patients with immune dysregulation. J. Autoimmun. 140, 103088 (2023).","journal-title":"J. Autoimmun."},{"key":"1291_CR146","doi-asserted-by":"publisher","unstructured":"Kotliar, D. et al. Reproducible single cell annotation of programs underlying T-cell subsets, activation states, and functions. Preprint at bioRxiv, https:\/\/doi.org\/10.1101\/2024.05.03.592310 (2024).","DOI":"10.1101\/2024.05.03.592310"},{"key":"1291_CR147","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25957-x","volume":"12","author":"JB Kang","year":"2021","unstructured":"Kang, J. B. et al. Efficient and precise single-cell reference atlas mapping with Symphony. Nat. Commun. 12, 5890 (2021).","journal-title":"Nat. Commun."},{"key":"1291_CR148","doi-asserted-by":"publisher","unstructured":"De Simone, M. et al. Comparative analysis of commercial single-cell RNA sequencing technologies. Preprint at bioRxiv, 2024.2006.2018.599579, https:\/\/doi.org\/10.1101\/2024.06.18.599579 (2024).","DOI":"10.1101\/2024.06.18.599579"},{"key":"1291_CR149","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.835760","volume":"13","author":"J Liu","year":"2022","unstructured":"Liu, J. et al. Combined single cell transcriptome and surface epitope profiling identifies potential biomarkers of psoriatic arthritis and facilitates diagnosis via machine learning. Front. Immunol. 13, 835760 (2022).","journal-title":"Front. Immunol."},{"key":"1291_CR150","first-page":"S20","volume":"21","author":"DL Scott","year":"2003","unstructured":"Scott, D. L., Smith, C. & Kingsley, G. Joint damage and disability in rheumatoid arthritis: an updated systematic review. Clin. Exp. Rheumatol. 21, S20\u2013S27 (2003).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1291_CR151","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1136\/annrheumdis-2011-201048","volume":"71","author":"RJ Wakefield","year":"2012","unstructured":"Wakefield, R. J. et al. After treat-to-target: can a targeted ultrasound initiative improve RA outcomes? Ann. Rheum. Dis. 71, 799\u2013803 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"1291_CR152","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/ng.1076","volume":"44","author":"S Raychaudhuri","year":"2012","unstructured":"Raychaudhuri, S. et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat. Genet. 44, 291\u2013296 (2012).","journal-title":"Nat. Genet."},{"key":"1291_CR153","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1038\/s41588-022-01213-w","volume":"54","author":"K Ishigaki","year":"2022","unstructured":"Ishigaki, K. et al. Multi-ancestry genome-wide association analyses identify novel genetic mechanisms in rheumatoid arthritis. Nat. Genet. 54, 1640\u20131651 (2022).","journal-title":"Nat. Genet."},{"key":"1291_CR154","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2025.152708","volume":"72","author":"GC McDermott","year":"2025","unstructured":"McDermott, G. C. et al. Polygenic risk scores for rheumatoid arthritis and idiopathic pulmonary fibrosis and associations with RA, interstitial lung abnormalities, and quantitative interstitial abnormalities among smokers. Semin. Arthritis Rheum. 72, 152708 (2025).","journal-title":"Semin. Arthritis Rheum."},{"key":"1291_CR155","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1136\/annrheumdis-2013-204133","volume":"74","author":"A Yarwood","year":"2015","unstructured":"Yarwood, A. et al. A weighted genetic risk score using all known susceptibility variants to estimate rheumatoid arthritis risk. Ann. Rheum. Dis. 74, 170\u2013176 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"1291_CR156","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1078\/0344-0338-5710261","volume":"198","author":"V Krenn","year":"2002","unstructured":"Krenn, V. et al. Grading of chronic synovitis \u2014 a histopathological grading system for molecular and diagnostic pathology. Pathol. Res. Pract. 198, 317\u2013325 (2002).","journal-title":"Pathol. Res. Pract."},{"key":"1291_CR157","doi-asserted-by":"publisher","first-page":"eaau8587","DOI":"10.1126\/scitranslmed.aau8587","volume":"11","author":"D Kuo","year":"2019","unstructured":"Kuo, D. et al. HBEGF+ macrophages in rheumatoid arthritis induce fibroblast invasiveness. Sci. Transl. Med. 11, eaau8587 (2019).","journal-title":"Sci. Transl. Med."},{"key":"1291_CR158","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/s41586-019-1263-7","volume":"570","author":"AP Croft","year":"2019","unstructured":"Croft, A. P. et al. Distinct fibroblast subsets drive inflammation and damage in arthritis. Nature 570, 246\u2013251 (2019).","journal-title":"Nature"},{"key":"1291_CR159","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41586-020-2222-z","volume":"582","author":"K Wei","year":"2020","unstructured":"Wei, K. et al. Notch signalling drives synovial fibroblast identity and arthritis pathology. Nature 582, 259\u2013264 (2020).","journal-title":"Nature"},{"key":"1291_CR160","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2022.104533","volume":"377","author":"W Bao","year":"2022","unstructured":"Bao, W., Xie, M. & Ye, Y. Age-associated B cells indicate disease activity in rheumatoid arthritis. Cell Immunol. 377, 104533 (2022).","journal-title":"Cell Immunol."},{"key":"1291_CR161","doi-asserted-by":"publisher","first-page":"755","DOI":"10.3389\/fimmu.2018.00755","volume":"9","author":"FAH Cooles","year":"2018","unstructured":"Cooles, F. A. H. et al. Phenotypic and transcriptomic analysis of peripheral blood plasmacytoid and conventional dendritic cells in early drug na\u00efve rheumatoid arthritis. Front. Immunol. 9, 755 (2018).","journal-title":"Front. Immunol."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-025-01291-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-025-01291-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-025-01291-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:02:15Z","timestamp":1761177735000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-025-01291-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":161,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1291"],"URL":"https:\/\/doi.org\/10.1038\/s41584-025-01291-0","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]},"assertion":[{"value":"24 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.A.R. reports grant support from Janssen, Merck and Bristol Myers Squibb outside of the current report, and reports personal fees from AstraZeneca, Merck, AbbVie, Biogen, Simcere, Epana, HiFiBio and Bristol Myers Squibb. He is co-inventor on a patent using T\n                      PH\n                      cells as a biomarker of autoimmune diseases.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}